IN2014CN02586A - - Google Patents

Download PDF

Info

Publication number: IN2014CN02586A
Authority: IN; India
Prior art keywords: receptor; endothelin; artificial transcription; toll; useful
Prior art date: 2011-10-11

Application number

Other languages

English (en)

Inventor

Josef Flammer

Albert Neutzner

Alice Huxley

Original Assignee

Aliophtha Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-10-11

Filing date

2012-10-10

Publication date

2015-08-07

2012-10-10 Application filed by Aliophtha Ag filed Critical Aliophtha Ag

2015-08-07 Publication of IN2014CN02586A publication Critical patent/IN2014CN02586A/en

Links

102000040945 Transcription factor Human genes 0.000 abstract 3
108091023040 Transcription factor Proteins 0.000 abstract 3
108020003175 receptors Proteins 0.000 abstract 3
102000002045 Endothelin Human genes 0.000 abstract 2
108050009340 Endothelin Proteins 0.000 abstract 2
102000009438 IgE Receptors Human genes 0.000 abstract 2
108010073816 IgE Receptors Proteins 0.000 abstract 2
102000008233 Toll-Like Receptor 4 Human genes 0.000 abstract 2
108010060804 Toll-Like Receptor 4 Proteins 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 abstract 2
208000023275 Autoimmune disease Diseases 0.000 abstract 1
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
208000003569 Central serous chorioretinopathy Diseases 0.000 abstract 1
102000030168 Endothelin A Receptor Human genes 0.000 abstract 1
108010090549 Endothelin A Receptor Proteins 0.000 abstract 1
102000013128 Endothelin B Receptor Human genes 0.000 abstract 1
108010090557 Endothelin B Receptor Proteins 0.000 abstract 1
208000001344 Macular Edema Diseases 0.000 abstract 1
206010025415 Macular oedema Diseases 0.000 abstract 1
206010061323 Optic neuropathy Diseases 0.000 abstract 1
201000007527 Retinal artery occlusion Diseases 0.000 abstract 1
208000007014 Retinitis pigmentosa Diseases 0.000 abstract 1
101710185494 Zinc finger protein Proteins 0.000 abstract 1
102100023597 Zinc finger protein 816 Human genes 0.000 abstract 1
230000000172 allergic effect Effects 0.000 abstract 1
208000010668 atopic eczema Diseases 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
208000030533 eye disease Diseases 0.000 abstract 1
208000014188 hereditary optic neuropathy Diseases 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
201000010230 macular retinal edema Diseases 0.000 abstract 1
230000030648 nucleus localization Effects 0.000 abstract 1
208000020911 optic nerve disease Diseases 0.000 abstract 1
108020001580 protein domains Proteins 0.000 abstract 1
230000018883 protein targeting Effects 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
102000005962 receptors Human genes 0.000 abstract 1
208000004644 retinal vein occlusion Diseases 0.000 abstract 1
230000026683 transduction Effects 0.000 abstract 1
238000010361 transduction Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Zoology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Ophthalmology & Optometry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicinal Preparation (AREA)

IN2586CHN2014 2011-10-11 2012-10-10 IN2014CN02586A (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP11184706		2011-10-11
PCT/EP2012/069981 WO2013053719A2 (en)	2011-10-11	2012-10-10	Regulation of receptor expression through delivery of artificial transcription factors

Publications (1)

Publication Number	Publication Date
IN2014CN02586A true IN2014CN02586A (de)	2015-08-07

Family

ID=47045011

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IN2586CHN2014 IN2014CN02586A (de)	2011-10-11	2012-10-10

Country Status (21)

Country	Link
US (1)	US20140296129A1 (de)
EP (1)	EP2766484A2 (de)
JP (1)	JP2014530607A (de)
KR (1)	KR20140079780A (de)
CN (1)	CN103998609A (de)
AU (1)	AU2012323032A1 (de)
BR (1)	BR112014008456A2 (de)
CA (1)	CA2851560A1 (de)
CL (1)	CL2014000897A1 (de)
CO (1)	CO6930308A2 (de)
EA (1)	EA201490531A1 (de)
HK (1)	HK1197083A1 (de)
IL (1)	IL231865A0 (de)
IN (1)	IN2014CN02586A (de)
MA (1)	MA36970A1 (de)
MX (1)	MX2014004331A (de)
PH (1)	PH12014500786A1 (de)
SG (1)	SG11201400701WA (de)
TN (1)	TN2014000117A1 (de)
WO (1)	WO2013053719A2 (de)
ZA (1)	ZA201401960B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2015311704B2 (en)	2014-09-07	2021-12-09	Selecta Biosciences, Inc.	Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses
AU2018347583A1 (en)	2017-10-13	2020-05-21	Selecta Biosciences, Inc.	Methods and compositions for attenuating anti-viral transfer vector IgM responses
WO2019195285A1 (en) *	2018-04-02	2019-10-10	University Of Miami	Ifn-beta reporter system for immortalized primary cells
CA3141863A1 (en)	2019-05-28	2020-12-03	Selecta Biosciences, Inc.	Methods and compositions for attenuated anti-viral transfer vector immune response
AU2020405068A1 (en)	2019-12-18	2022-07-07	Stinginn Llc	Substituted 1,2, 4-triazoles and methods of use
CN111304314B (zh) *	2020-02-25	2020-11-20	四川省人民医院	Znf124基因在视网膜色素变性疾病早期筛查或辅助诊断中的应用
US20220049310A1 (en) *	2020-02-25	2022-02-17	Sichuan Provincial People's Hospital	Use of ZNF124 Gene in Early Screening or Auxiliary Diagnosis of Retinitis Pigmentosa Disease
US11897888B1 (en)	2020-04-30	2024-02-13	Stinginn Llc	Small molecular inhibitors of sting signaling compositions and methods of use
WO2023064367A1 (en)	2021-10-12	2023-04-20	Selecta Biosciences, Inc.	Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2023172624A1 (en)	2022-03-09	2023-09-14	Selecta Biosciences, Inc.	Immunosuppressants in combination with anti-igm agents and related dosing

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE524545T1 (de) *	1994-08-20	2011-09-15	Gendaq Ltd	Verbesserungen bei oder im zusammenhang mit bindeproteinen zur erkennung von dna
US6534261B1 (en) *	1999-01-12	2003-03-18	Sangamo Biosciences, Inc.	Regulation of endogenous gene expression in cells using zinc finger proteins
AU2964101A (en) *	2000-01-21	2001-07-31	Scripps Research Institute, The	Methods and compositions to modulate expression in plants
US20020061512A1 (en) *	2000-02-18	2002-05-23	Kim Jin-Soo	Zinc finger domains and methods of identifying same
NZ527476A (en) *	2001-02-21	2006-06-30	Novartis Ag	Zinc finger binding domains for nucleotide sequence ANN
US20030077279A1 (en) *	2001-10-24	2003-04-24	Cedars-Sinai Medical Center	Methods for treating vascular disease by inhibiting toll-like receptor-4
US20060094676A1 (en) *	2004-10-29	2006-05-04	Ronit Lahav	Compositions and methods for treating cancer using compositions comprising an inhibitor of endothelin receptor activity
EP1929032A4 (de) *	2005-09-30	2009-11-04	Oklahoma Med Res Found	Regulierung von toll-like-rezeptoren auf stammzellen
WO2008140538A1 (en) *	2006-10-04	2008-11-20	Verenium Corporation	Dna display screen for expression product with desired binding properties
GB0620705D0 (en) *	2006-10-18	2006-11-29	Opsona Therapeutics	Compounds for the modulation of toll-like receptor activity and assay methods for the identification of said compounds
CN101333251A (zh) *	2008-01-30	2008-12-31	中国人民解放军第三军医大学	能启动a20基因表达的人工锌指蛋白转录因子及用途
US20110318830A1 (en) *	2008-11-12	2011-12-29	The Regents Of The University Of California	Compositions and methods for re-programming and re-differentiating cells
EP2411518A2 (de) *	2009-03-27	2012-02-01	Merck Sharp&Dohme Corp.	Rna-interferenz-vermittelte hemmung der genexpression von fcerla (hochaffiner-ige-rezeptor-alpha-kette) unter verwendung von sina (short interfering nucleic acid)
EP2509594A1 (de) *	2009-12-09	2012-10-17	INSERM - Institut National de la Santé et de la Recherche Médicale	Endothelin-hemmer zur behandlung von rasch progressiver glomerulonephritis

2012
- 2012-10-10 IN IN2586CHN2014 patent/IN2014CN02586A/en unknown
- 2012-10-10 CA CA2851560A patent/CA2851560A1/en not_active Abandoned
- 2012-10-10 US US14/349,443 patent/US20140296129A1/en not_active Abandoned
- 2012-10-10 AU AU2012323032A patent/AU2012323032A1/en not_active Abandoned
- 2012-10-10 CN CN201280049781.2A patent/CN103998609A/zh active Pending
- 2012-10-10 WO PCT/EP2012/069981 patent/WO2013053719A2/en not_active Ceased
- 2012-10-10 PH PH1/2014/500786A patent/PH12014500786A1/en unknown
- 2012-10-10 BR BR112014008456A patent/BR112014008456A2/pt not_active IP Right Cessation
- 2012-10-10 EA EA201490531A patent/EA201490531A1/ru unknown
- 2012-10-10 MA MA36970A patent/MA36970A1/fr unknown
- 2012-10-10 EP EP12774996.8A patent/EP2766484A2/de not_active Withdrawn
- 2012-10-10 JP JP2014535033A patent/JP2014530607A/ja active Pending
- 2012-10-10 SG SG11201400701WA patent/SG11201400701WA/en unknown
- 2012-10-10 KR KR1020147009933A patent/KR20140079780A/ko not_active Withdrawn
- 2012-10-10 MX MX2014004331A patent/MX2014004331A/es unknown
- 2012-10-10 HK HK14110571.0A patent/HK1197083A1/xx unknown
2014
- 2014-03-18 ZA ZA2014/01960A patent/ZA201401960B/en unknown
- 2014-03-19 TN TNP2014000117A patent/TN2014000117A1/en unknown
- 2014-04-01 IL IL231865A patent/IL231865A0/en unknown
- 2014-04-09 CO CO14077166A patent/CO6930308A2/es unknown
- 2014-04-10 CL CL2014000897A patent/CL2014000897A1/es unknown

Also Published As

Publication number	Publication date
BR112014008456A2 (pt)	2017-04-11
ZA201401960B (en)	2015-06-24
MX2014004331A (es)	2014-11-26
EA201490531A1 (ru)	2014-08-29
IL231865A0 (en)	2014-05-28
EP2766484A2 (de)	2014-08-20
CL2014000897A1 (es)	2014-11-21
SG11201400701WA (en)	2014-08-28
AU2012323032A1 (en)	2014-04-03
JP2014530607A (ja)	2014-11-20
KR20140079780A (ko)	2014-06-27
PH12014500786A1 (en)	2021-08-09
HK1197083A1 (en)	2015-01-02
CA2851560A1 (en)	2013-04-18
WO2013053719A3 (en)	2013-06-27
MA36970A1 (fr)	2016-03-31
CO6930308A2 (es)	2014-04-28
CN103998609A (zh)	2014-08-20
US20140296129A1 (en)	2014-10-02
TN2014000117A1 (en)	2015-07-01
WO2013053719A2 (en)	2013-04-18

Publication	Publication Date	Title
IN2014CN02586A (de)	2015-08-07
Seiler et al.	2012	Cell replacement and visual restoration by retinal sheet transplants
PH12015502421A1 (en)	2016-02-22	Artificial transcription factors engineered to overcome endosomal entrapment
EP4477233A3 (de)	2025-03-26	Stabile flüssige formulierung von fusionsprotein mit igg-fc-domäne
ZA201705628B (en)	2024-08-28	Methods and compositions for treating genetic eye diseases
EP4248971A3 (de)	2024-02-14	Zusammensetzungen und verfahren zur verwendung von nintedanib zur behandlung von augenerkrankungen mit abnormaler neovaskularisation
MX2015006859A (es)	2016-02-05	Anticuerpos anti-vegf y sus usos.
SG10201805411YA (en)	2018-08-30	Chimeric antigen receptors
MY176514A (en)	2020-08-12	Compositions and methods for treating ocular edema, neovascularization and related diseases
CN104245736A (zh)	2014-12-24	抗人死亡受体5胞外区的人源化单克隆抗体
EA200901067A1 (ru)	2010-02-26	Использование семафорина 6а в качестве промотора миелинизации и дифференцировки олигодендроцитов
EP3989982A4 (de)	2023-06-28	Verstärkung einer aav-vermittelten transduktion von augengeweben mit hyaluronsäure
EP4389894A3 (de)	2024-08-28	Riboswitch-modulierte gentherapie für netzhauterkrankungen
TN2015000436A1 (en)	2017-01-03	Artificial transcription factors for the treatment of diseases caused by opa1 haploinsufficiency
MX391658B (es)	2025-03-21	Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular
WO2012012798A3 (en)	2012-04-19	Materials and methods for reduction of protein tau and treatment of neurodegenerative diseases
ZA202206245B (en)	2023-11-29	On-bipolar cell-specific promoters for ocular gene delivery
EP4028037A4 (de)	2023-06-28	Verfahren zur behandlung von neovaskulären erkrankungen unter verwendung von aav2-varianten, die für aflibercept kodieren
WO2013062258A3 (ko)	2013-06-20	감자 유래의 괴경 조직 특이적 라케이즈 프로모터 및 이의 용도
HK40066503A (en)	2022-08-19	Anti-sema3a antibodies and their uses for treating eye or ocular diseases
MY178716A (en)	2020-10-20	Composition for treatment of ocular diseases and preparation thereof
HK40077797A (en)	2023-03-17	Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept
Nan-Kai et al.	2010	Transplantation of reprogrammed embryonic stem cells improves visual function in a mouse model for Retinitis Pigmentosa: Transplantation 2010 April 27; 89 (8): 911-919.
NZ745944B2 (en)	2025-09-02	Fusion proteins of pd-1 and 4-1bb
CY1115193T1 (el)	2017-01-04	Μεθοδοι και συνθεσεις για προληπτικη ή θεραπευτικη αγωγη οφθαλμικων παθησεων